Micrograph News and Research

RSS

Large SARS-CoV-2 outbreak on a fishing boat - neutralizing antibodies prevent infection

Now, a team of researchers at the University of Washington School of Medicine has found evidence that SARS-CoV-2 neutralizing antibodies can prevent infection in people, as they conducted a study before and after a COVID-19 outbreak on a fishing vessel.

19 Aug 2020

Multiplication of ecDNA genes present in many cancer types, drives poor patients outcomes

The multiplication of genes located in extrachromosomal DNA that have the potential to cause cancer drives poor patient outcomes across many cancer types, according to a Nature Genetics study published Aug. 17, 2020 by a team of researchers including Professors Vineet Bafna and Dr.Paul Mischel of the University of California San Diego and Professor Roel Verhaak of Jackson Laboratories.

17 Aug 2020

Pre-COVID-19 coronavirus immunity does not protect against SARS-CoV-2

A recent study by researchers in France that's currently available on the medRxiv* preprint server claims that having previous immunity against common coronaviruses (alpha and beta) cannot protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Aug 2020

Can the coronavirus SARS-CoV-2 be spread through frozen food?

It is well-known that the coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can spread through respiratory droplets when people sneeze, cough, or talk. Recent evidence has also shown that the virus can hang in the air for hours, hinting at the possibility of airborne transmission.

17 Aug 2020

Influenza-virus-based vaccine platform another viable option against SARS-CoV-2

In a novel proof of concept study, published on the bioRxiv preprint server, U.S. researchers used attenuated influenza viral particles that express severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain to induce neutralizing antibodies in mice – unveiling another viable vaccine candidate for preventing coronavirus disease (COVID-19).

14 Aug 2020

Membrane nanoparticles acts as a bait to trap SARS-CoV-2

In an exciting new bioRxiv preprint research paper, Chinese researchers describe the development of membrane nanoparticles from ACE2-rich cells with a potent capacity to block the adherence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

13 Aug 2020

A triplex SARS-CoV-2 assay based on nanopore sequencing is accurate, rapid and scalable

A novel breakthrough by a research group from Oxford Nanopore Technologies is a rapid way of testing and screening large numbers of samples for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

12 Aug 2020

SARS-CoV-2 a "swarm" of mutant viruses

In this new study, the virus was serially passaged in independent cell types in a controlled environment. The researchers found that the virus rapidly adapts to the changing conditions in culture by selecting for pre-existing species.

12 Aug 2020

Can SARS-CoV-2 be transmitted via feces?

A new study by researchers at the University of Oxford and the Trip Medical Database and published on the preprint server medRxiv* in August 2020 as part of the ongoing Open Evidence Review on Transmission Dynamics of COVID-19 reports the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in feces and the need for precautions to prevent orofecal spread in the surroundings of confirmed or suspected cases.

12 Aug 2020

Inhaled delivery of a potent neutralizing nanobody effective against SARS-CoV-2

A recent study by researchers from China, available on the bioRxiv preprint server, shows how stable neutralizing nanobody Nb11-59 might be a promising prophylactic and therapeutic molecule against coronavirus disease (COVID-19) – especially if administered via the inhalatory route.

11 Aug 2020

Vaccine 'nationalism' will slow coronavirus fight if poor countries are left exposed

As the coronavirus vaccine race charges on, many of the investigational candidate vaccines are nearing the final stages of human trials. The results of these trials will determine if they will be granted the green light to manufacture and distribute the vaccine to countries across the globe.

10 Aug 2020

Speed of Novavax vaccine development does not compromise quality of the SARS-CoV-2 immunogen

A new study by researchers from the Scripps Research Institute and Novavax Inc. in the US affirms the structural integrity of the full-length SARS-CoV-2 spike glycoprotein immunogen. It enables the interpretation of immune responses to this multivalent nanoparticle immunogen. Their results are currently available on bioRxiv preprint server.

9 Aug 2020

Heat suggested as a therapeutic intervention in COVID-19

Viruses that are contained within a lipid membrane or “enveloped viruses” such as coronaviruses and rhinoviruses can remain active for long periods in cool, dry conditions, which can lead to increased rates of respiratory infections.

6 Aug 2020

Mice study shows a promising therapy for spinal cord injuries

Using stem cells to restore lost functions due to spinal cord injury (SCI) has long been an ambition of scientists and doctors.

6 Aug 2020

Regeneron's COVID-19 antibody-drug cocktail treats SARS-CoV-2 virus in animals

Now, Regeneron Pharmaceuticals says its COVID-19 antibody-drug cocktail under development prevented and treated the disease in monkeys and hamsters, showing promise that it may work in humans.

5 Aug 2020

NIH trial to evaluate potential new therapeutics for mild, moderate COVID-19

A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease.

4 Aug 2020

Clinical trial to test safety, efficacy of antibody treatment in hospitalized COVID-19 patients

Patients admitted with COVID-19 at select hospitals may now volunteer to enroll in a clinical trial to test the safety and efficacy of a potential new treatment for the disease.

4 Aug 2020

SARS-CoV-2 lured away and trapped by a new decoy version of ACE2

Researchers in the United States and Canada have engineered affinity-optimized “receptor traps” that prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from binding to and infecting cells.

3 Aug 2020

SARS-CoV-2 spike protein recognized by innate immune receptors in a glycan-dependent way

The spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) depends on its ability to infect new host cells following its replication and release from infected cells. This pivots on its ability to bind to cell surface receptors like the ACE2 enzyme.

3 Aug 2020

Severe fatigue common in COVID-19, independent of disease severity

Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection often complain of fatigue, but now a new study shows that it also causes severe and frequent fatigue in those who recover after mild illness too.

2 Aug 2020

Micrograph News and Research

Large SARS-CoV-2 outbreak on a fishing boat - neutralizing antibodies prevent infection

Multiplication of ecDNA genes present in many cancer types, drives poor patients outcomes

Pre-COVID-19 coronavirus immunity does not protect against SARS-CoV-2

Can the coronavirus SARS-CoV-2 be spread through frozen food?

Influenza-virus-based vaccine platform another viable option against SARS-CoV-2

Membrane nanoparticles acts as a bait to trap SARS-CoV-2

A triplex SARS-CoV-2 assay based on nanopore sequencing is accurate, rapid and scalable

SARS-CoV-2 a "swarm" of mutant viruses

Can SARS-CoV-2 be transmitted via feces?

Inhaled delivery of a potent neutralizing nanobody effective against SARS-CoV-2

Vaccine 'nationalism' will slow coronavirus fight if poor countries are left exposed

Speed of Novavax vaccine development does not compromise quality of the SARS-CoV-2 immunogen

Heat suggested as a therapeutic intervention in COVID-19

Mice study shows a promising therapy for spinal cord injuries

Regeneron's COVID-19 antibody-drug cocktail treats SARS-CoV-2 virus in animals

NIH trial to evaluate potential new therapeutics for mild, moderate COVID-19

Clinical trial to test safety, efficacy of antibody treatment in hospitalized COVID-19 patients

SARS-CoV-2 lured away and trapped by a new decoy version of ACE2

SARS-CoV-2 spike protein recognized by innate immune receptors in a glycan-dependent way

Severe fatigue common in COVID-19, independent of disease severity

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News